Why Some Employers Split Pharmacy from Medical, and What Can Go Wrong

The CFO at a 600-employee tech firm calls an emergency meeting: pharmacy spend just hit $1.7 million this year, up 19%. Their fully insured medical carrier says Rx costs are "baked in" and offers vague promises about future rebates. A broker floats the idea of carving out pharmacy with an independent PBM, promising more control and rebate transparency. Should the employer jump?

Over half of U.S. self-funded employers choose a pharmacy carve-out, hoping for lower cost, better reporting, and direct contract terms. Carriers like UnitedHealthcare and Aetna bundle medical and Rx, often keeping formulary, claims, and rebates under a single dashboard. Carve-out means splitting the benefit: medical with one vendor (TPA or carrier), pharmacy with another (like CVS Caremark, Express Scripts, OptumRx, or a transparent PBM such as Navitus, Capital Rx, or RxBenefits).

The promise: improved financial transparency, potential for aggressive prescription cost management, and less "cross-subsidizing" of one benefit by another. But carve-out is no silver bullet. Poor file feeds, lingering medical-pharmacy disconnects, and employee confusion can eat up savings. The worst-case scenario? An employer moves to carve-out, only to discover new headaches and no net savings.

When Carve-Out Delivers Savings, and When It Doesn’t

The math behind carve-out is rarely as simple as a PBM sales pitch. Here's what matters most:

• Plan size: A 500-life group gets a very different deal than a 10,000-life system. Small employers may lack scale to move the rebate needle.
• Rx trend drivers: Is your spend driven by high-cost specialty drugs (think Humira, Ozempic, or Skyrizi), or is it generics, antibiotics, and low-cost maintenance meds?
• Rebate transparency: Carved-in plans often see net costs bundled, making it tough to confirm rebate pass-through. With carve-out, you can audit and reconcile rebate payments, but you have to monitor them.
• Stop-loss coordination: Does your stop-loss carrier require integrated Rx and medical for "laser" protection? Will carving out push up your specific or aggregate premium?
• Management resources: Who on your team will coordinate separate vendors, eligibility files, and member escalations?

Here's a real scenario. A 1,200-employee manufacturer spent $2.9M/year on pharmacy within a bundled medical/Rx contract. Their medical carrier projected a 15% pharmacy trend for renewal, based mostly on specialty drug inflation and new GLP-1 utilization. By carving out pharmacy with an independent PBM and working with a pharmacy benefits consultant, they negotiated a new formulary with exclusions, implemented copay assistance for specialty, and secured 95% rebate pass-through. First year, net pharmacy spend dropped to $2.2M. But savings weren't automatic, they required tight eligibility file management, biweekly calls between TPA and PBM, and ongoing disruption mitigation for employees cut from branded drugs.

On the other hand, a 300-life nonprofit spent $420,000 on pharmacy carved into their medical plan. Their data showed 92.5% GDR, under 10% specialty spend, and no active high-cost claimants. A carve-out would have meant higher admin fees and minimal negotiating power, modeling showed maybe $10,000 in annual net savings, likely wiped out by member disruption and extra HR time.

How to Analyze Your Situation and Decide

Pull three years of medical and pharmacy claims (not just high-level summaries). Ask your current carrier or TPA for a full eligibility and utilization file. Then, work with a pharmacy benefits consultant or actuarial firm to run these steps:

1. Benchmark your numbers. How do your PMPM pharmacy costs ($100-$140 typical), GDR (88-92%), and specialty as a % of spend (50-55%) compare to industry benchmarks? If you're much higher, carve-out may help. If you're already low, savings are harder to find.
2. Model savings with real drug pricing. Use a drug claim repricing tool like RxInfo.ai or contract samples from a PBM RFP to forecast net cost under carve-out. Include rebates, fees, and clinical program costs.
3. Check stop-loss impact. Get your stop-loss broker or actuary to estimate rate changes if you split the benefits. Expect higher rates or less coverage for specialty-heavy populations, sometimes a carve-in deal absorbs more risk.
4. Factor in member disruption. Estimate how many employees would need to switch pharmacies, drugs, or prior authorizations. Ask the prospective PBM for disruption reports based on your claims.
5. Plan for integration hurdles. Who on your HR/benefits team owns eligibility files? Medical and pharmacy vendors must be in sync weekly to avoid coverage lapses. Will you need outside help for implementation?

Expect the process to take 4-6 months from initial analysis to a go-live, especially if you want competitive bids. Engage your ERISA attorney early to review contract terms and fiduciary responsibilities.

Practical Steps for a Smooth Transition, Or a Smart Decision to Stay Bundled

If your analysis shows savings potential, build your timeline backward from your medical renewal date. Issue the PBM RFP at least 180 days before renewal. Demand full data feeds from the carrier, some will delay or limit access until you commit to carve-out.

Communicating with employees is important. Plan for clear, frequent updates about new ID cards, pharmacy network changes, and any formulary exclusions. Use resources like ClinicalRx.ai for member-facing drug comparisons and answers on clinical equivalence.

Don't overlook post-implementation. Monthly claims audits, rebate reconciliations, and member issue tracking quickly reveal if the carve-out is delivering promised value. If not, you still have leverage for corrections at renewal.

For groups with under 500 employees, carve-out rarely delivers more than incremental savings unless you have complex claims, specialty concentration, or rapid utilization spikes. If you choose to stay bundled, negotiate for explicit pharmacy reporting, audit rights, and a plan to address high-cost claimants. Either way, the status quo is rarely optimal.

If you do nothing else this quarter, pull your pharmacy and medical claims detail and run your numbers against the latest benchmarks. Find out where your real risks, and opportunities, are hiding.